Thinly traded nano cap Outlook Therapeutics (OTLK +49.3%) is up on a healthy 24x surge in volume on the heels of the FDA’s sign-off on protocols for three new Phase 3 studies supporting ONS-5010, an ophthalmic formulation of Roche’s cancer med Avastin (bevacizumab).
The three studies are: NORSE 4, in patients with branch retinal vein occlusion (BRVO) and NORSE 5 & 6 in diabetic macular edema patients. All should launch in 2020 after enrollment is completed in NORSE 2 in wet AMD. If all goes well, the company expects to launch commercially in 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.